Managing bleeding in anticoagulated patients in the emergency care setting

Journal of Emergency Medicine

Volumn 45, Issue 3, 2013, Pages 467-477

  Pollack, Charles V ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

anticoagulant; antidote; bleeding; dabigatran; rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; DABIGATRAN ETEXILATE; FRESH FROZEN PLASMA; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANAPHYLAXIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG HALF LIFE; DRUG MONITORING; DRUG USE; EMERGENCY CARE; EMERGENCY MEDICINE; EMERGENCY SURGERY; EMERGENCY WARD; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANT; ANTIDOTE; BLEEDING; DABIGATRAN; RIVAROXABAN;

ANTICOAGULANTS; ANTIDOTES; BENZIMIDAZOLES; BETA-ALANINE; EMERGENCY SERVICE, HOSPITAL; HEMORRHAGE; HEMOSTASIS; HUMANS; MORPHOLINES; THIOPHENES; WARFARIN;

EID: 84883458920     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2013.03.016     Document Type: Article

References (69)

1. T. Zögg, and H. Brandstetter Complex assemblies of factors ix and x regulate the initiation, maintenance, and shutdown of blood coagulation Prog Mol Biol Transl Sci 99 2011 51 103
2. J. Arnout, M.F. Hoylaerts, and H.R. Lijnen Haemostasis Handb Exp Pharmacol 176 Pt 2 2006 1 41
3. R.L. Silverstein, K.A. Bauer, and M. Cushman Venous thrombosis in the elderly: more questions than answers Blood 110 2007 3097 3101
4. M. Cushman Epidemiology and risk factors for venous thrombosis Semin Hematol 44 2007 62 69
5. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 e354
6. J.J. You, D.E. Singer, and P.A. Howard Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e531S e575S
7. W. Ageno, A.S. Gallus, A. Wittkowsky, M. Crowther, E.M. Hylek, and G. Palareti Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e44S e88S
8. B. Furie, B.A. Bouchard, and B.C. Furie Vitamin k-dependent biosynthesis of gamma-carboxyglutamic acid Blood 93 1999 1798 1808
9. A.M. Holbrook, J.A. Pereira, and R. Labris Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 2005 1095 1100
10. D.K. Wysowski, P. Nourjah, and L. Swartz Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action Arch Intern Med 167 2007 1414 1419
11. Y. Miyasaka, M.E. Barnes, and B.J. Gersh Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study Stroke 36 2005 2362 2366
12. Intermountain Joint Replacement Center Writing Committee A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty J Arthroplasty 27 2012 1 9 e2. Available at: http://www.arthroplastyjournal.org/article/S0883-5403(11)00144-6/abstract Accessed October 26, 2011
13. P. Mismetti, S. Laporte, and P. Zufferey Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis J Thromb Haemost 2 2004 1058 1070
14. L.A. Dossett, J.N. Riesel, M.R. Griffin, and B.A. Cotton Prevalence and implications of preinjury warfarin use: an analysis of the national trauma databank Arch Surg 146 2011 565 570
15. D.S. Budnitz, M.C. Lovegrove, and N. Shehab Emergency hospitalizations for adverse drug events in older Americans N Engl J Med 365 2011 2002 2012
16. S.J. Connolly, M.D. Ezekowitz, S. Yusuf RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
17. ® (dabigatran etexilate mesylate) capsules for oral use. 2013. Available at: http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed May 28, 2013.
18. L.S. Wann, A.B. Curtis, and K.A. Ellenbogen 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 1144 1150
19. K. Kirley, D.M. Qato, R. Kornfield, R.S. Stafford, and G.C. Alexander National trends in oral anticoagulant use in the United States, 2007 to 2011 Circ Cardiovasc Qual Outcomes 5 2012 615 621
20. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303
21. M.R. Patel, K.W. Mahaffey, J. Garg ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
22. ® (rivaroxaban) tablets for oral use. Available at: http://www.xareltohcp.com/sites/default/files/shared/xarelto-0.pdf#zoom=100. Accessed November 27, 2012.
23. C.B. Granger, J.H. Alexander, J.J. McMurray ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
24. S.J. Connolly, J. Eikelboom, C. Joyner AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
25. M.S. Da Silva, and M. Sobel Anticoagulants: to bleed or not to bleed, that is the question Semin Vasc Surg 15 2002 256 267
26. J.P. DiMarco, G. Flaker, and A.L. Waldo Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the atrial fibrillation follow-up investigation of rhythm management (affirm) study Am Heart J 149 2005 650 656
27. R. Pisters, D.A. Lane, and R. Nieuwlaat A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
28. D. Mountain, V. Sistenich, and I.G. Jacobs Characteristics, management and outcomes of adults with major trauma taking pre-injury warfarin in a western Australian population from 2000 to 2005: a population-based cohort study Med J Aust 193 2010 202 206
29. F.A. Ivascu, R.J. Janczyk, and F.S. Junn Treatment of trauma patients with intracranial hemorrhage on preinjury warfarin J Trauma 61 2006 318 321
30. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) study group Ann Neurol 42 1997 857 865
31. J. Hirsh, V. Fuster, J. Ansell, and J.L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy Circulation 107 2003 1692 1711
32. ® for injection. 2005. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/009218s101lbl.pdf. Accessed July 28, 2011.
33. C.J. Wiedermann, and I. Stockner Warfarin-induced bleeding complications - clinical presentation and therapeutic options Thromb Res 122 Suppl 2 2008 S13 S18
34. H.G. Watson, T. Baglin, S.L. Laidlaw, M. Makris, and F.E. Preston A comparison of the efficacy and rate of response to oral and intravenous vitamin k in reversal of over-anticoagulation with warfarin Br J Haematol 115 2001 145 149
35. A. Lubetsky, H. Yonath, and D. Olchovsky Comparison of oral vs intravenous phytonadione (vitamin k1) in patients with excessive anticoagulation: a prospective randomized controlled study Arch Intern Med 163 2003 2469 2473
36. J.P. Hanley Warfarin reversal J Clin Pathol 57 2004 1132 1139
37. L.B. Morgenstern, J.C. Hemphill 3rd, and C. Anderson Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 41 2010 2108 2129
38. J. Elliott, and M. Smith The acute management of intracerebral hemorrhage: a clinical review Anesth Analg 110 2010 1419 1427
39. J.N. Goldstein, S.H. Thomas, and V. Frontiero Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage Stroke 37 2006 151 155
40. R.E. O'Connor, W. Brady, and S.C. Brooks Part 10: acute coronary syndromes: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care Circulation 122 2010 S787 S817
41. E.C. Jauch, B. Cucchiara, and O. Adeoye Part 11: adult stroke: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care Circulation 122 2010 S818 S828
42. W.G. Eisert, N. Hauel, and J. Stangier Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin Arterioscler Thromb Vasc Biol 30 2010 1885 1889
43. J. Van Ryn, T. Litzenburger, and J. Schurer Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment) Circulation 126 2012 A9928
44. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 2008 285 295
45. J. Van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
46. J. Stangier, K. Rathgen, H. Stähle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
47. F. Wagner, H. Peters, and S. Formella Effective elimination of dabigatran with haemodialysis: a phase I single centre study in patients with end-stage renal disease Circulation 124 2011 A13303 Available at: http://circ.ahajournals. org/cgi/content/meeting
48. B.I. Eriksson, D.J. Quinlan, and J.I. Weitz Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development Clin Pharmacokinet 48 2009 1 22
49. W. Zhou, S. Schwarting, and S. Illanes Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran Stroke 42 2011 3594 3599
50. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
51. W. Zhou, R. Veltkamp, and S. Schwarting Response to letter by Moll regarding article, 'Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran' Circulation 43 2012 e25
52. M.C. Matute, M. Guillán, and J. García-Caldentey Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran Thromb Haemost 106 2011 178 179
53. A. De Smedt, S. De Raedt, K. Nieboer, J. De Keyser, and R. Brouns Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran Cerebrovasc Dis 30 2010 533 534
54. Boehringer Ingelheim and the PHRI (of MacMaster University and Hamilton Health Sciences). RELY-ABLE trial emergency information: acute myocardial infarction. Available at: https://www.rely-able-trial.com/Rely2Web/resources/ jsp/emergency/myocInf.jsp. Accessed November 23, 2011.
55. L. Baruch, and O. Sherman Potential inaccuracy of point-of-care INR in dabigatran-treated patients Ann Pharmacother 45 2011 e40
56. T.L. Lindahl, F. Baghaei, I.F. Blixter Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 105 2011 371 378
57. R. Wilcox, R.C. Pendleton, K.J. Smock, and G.M. Rodgers Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice Hosp Pract (1995) 39 2011 23 34
58. G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement Thromb Res 127 2011 457 465
59. E. Perzborn, S. Roehrig, and A. Straub Rivaroxaban: a new oral factor Xa inhibitor Arterioscler Thromb Vasc Biol 30 2010 376 381
60. E. Perzborn, J. Strassburger, and A. Wilmen In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
61. G. Lu, F.R. Deguzman, and M.J. Karbarz Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445) Eur Heart J 32 Abstract Suppl 2011 640 641 Available at: http://spo.escardio.org/AbstractDetails.aspx?id=99309&eevtid=48 Accessed October 26, 2011
62. European Medicines Agency. Summary of product characteristics. Xarelto 10 mg film-coated tablets. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed October 25, 2011.
63. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880
64. D. Kubitza, M. Becka, and W. Mueck Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor Br J Clin Pharmacol 70 2010 703 712
65. J.L. Mega, E. Braunwald, S.D. Wiviott ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19 Available at: http://www.nejm.org/doi/suppl/10.1056/NEJMoa1112277/ suppl-file/nejmoa1112277-protocol.pdf Accessed November 30, 2011
66. E. Lindhoff-Last, M.M. Samama, T.L. Ortel, J.I. Weitz, and T.E. Spiro Assays for measuring rivaroxaban: their suitability and limitations Ther Drug Monit 32 2010 673 679
67. M.M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma Thromb Haemost 104 2010 1078 1079
68. European Medicines Agency. Summary of product characteristics. ELIQUIS 2.5 mg film-coated tablets. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002148/WC500107728.pdf. Accessed October 25, 2011.
69. Y.C. Barrett, Z. Wang, C. Frost, and A. Shenker Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Thromb Haemost 104 2010 1263 1271